News

At SLEEP 2026, the head of Orexin Franchise Development and Neuroscience Programs at Takeda discussed new phase 3 data of oveporexton in patients with narcolepsy type 1. [WATCH TIME: 5 minutes]

At SLEEP 2026, the research intern at Beth Israel Deaconess Medical Center described the development of an electronic health record–based machine learning model for obstructive sleep apnea screening. [WATCH TIME: 3 minutes]

Laura Nisenbaum, PhD, Interim Chief Science Officer at the Alzheimer's Drug Discovery Foundation, shares her perspective on the FDA's approval of a subcutaneous starting dose for lecanemab and what it means for access, clinical practice, and the future of Alzheimer disease treatment.

The FDA granted Priority Review to zeleciment rostudirsen for exon 51-amenable Duchenne muscular dystrophy, with a PDUFA target action date of January 21, 2027.

Understanding how amyloid pathology develops years before symptoms emerge is essential to appreciating the growing role of blood-based biomarkers in earlier Alzheimer disease detection.

The $100 million PROTECT-Cog trial will test whether adding a GLP-1 drug to the proven U.S. POINTER lifestyle intervention further cuts dementia risk in at-risk older adults.

Here's some of what is coming soon to NeurologyLive® this week.

PrevenTRON, a study of trontinemab, will enroll 1600 cognitively unimpaired participants identified by elevated plasma p-tau217, using time to clinical progression as the primary endpoint.

SAR448851 showed favorable safety, high CNS penetration, and up to 50% reductions in CSF soluble TREM2 in phase 1, supporting the design of TREMHANCE, a phase 2 trial now in final planning with p-tau217 as its primary endpoint.

At SLEEP 2026, the sleep medicine specialist at University of Arizona discussed the new American Academy of Sleep Medicine guideline on the use of combination therapy in adults with chronic insomnia. [WATCH TIME: 5 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 17, 2026.

At SLEEP 2026, a sleep medicine specialist at Mayo Clinic talked about the 2026 Restless Legs Syndrome Foundation algorithm, recently published in Mayo Clinic Proceedings. [WATCH TIME: 10 minutes]

Mitzi Joi Williams, MD, is joined by Jacquelyn McEwen, MD, and Jacqueline Rosenthal, MD, to discuss the latest updates to MS diagnostic criteria and their impact on diagnosing MS and NMOSD.

The global phase 3 registration trial enrolled 1535 patients across 240 sites and has completed its 52-week double-blind treatment phase, with no unexpected safety signals observed, even in participants on concomitant antiamyloid therapies.

A cross-sectional survey of 4181 NARCOMS Registry participants found that only 7.4% had ever used semaglutide or tirzepatide, despite 40% meeting FDA-approved indications for the drugs.

Across 3 first-in-human studies in healthy volunteers and cognitively impaired adults, MK-2214 demonstrated dose-proportional pharmacokinetics, an approximately 80-day half-life, and near-complete suppression of free pS413 tau in CSF at doses of 20 mg and above.

Arif Dalvi, MD, director of the Comprehensive Movement Disorders Center at Palm Beach Health Network in Florida, discusses new Lancet Neurology data on staged bilateral focused ultrasound for Parkinson disease motor complications.

If approved, AD109 could become the first medication to address both the nighttime airway obstruction and oxygen deprivation central to OSA, as well as its daytime symptoms, such as fatigue.

The FDA files the NDA for Axsome’s AXS-12 for cataplexy in narcolepsy, backed by phase 3 data wins showing fewer attacks and better daytime alertness.

The assistant professor in the Department of Behavioral Science at the University of Kentucky discusses a nonpharmacologic intervention designed to address sensory processing impairments in older adults with dementia. [WATCH TIME: 5 minutes]

At AAIC 2026, the senior research professor of neurology at Indiana University School of Medicine discussed the evolving role of blood-based Alzheimer disease biomarkers, particularly p-tau217.

At AAIC 2026, professor of neurology at Washington University in St. Louis discussed how integrating clinical assessment with amyloid biomarkers can improve diagnostic accuracy in Alzheimer disease. [WATCH TIME: 5 minutes]

The 60 mg dose showed the largest treatment effect, slowing decline by 26% on CDR-SB, 42% on ADAS-Cog13, and 50% on MMSE at 18 months, while all doses produced 50% to 65% reductions in CSF total tau and unprecedented tau PET reductions across brain regions.

At AAIC 2026, associate professor of neurology at Albert Einstein College of Medicine discussed a culinary medicine intervention to improve MIND diet adherence and mood in older adults with type 2 diabetes. [WATCH TIME: 5 minutes]

MCLENA-1 enrolled only 6 completers due to funding constraints but demonstrated 12 months of continuous lenalidomide was safe and tolerable, with nonsignificant trends favoring treatment on cognition and global outcomes.

In a single-center retrospective analysis, approximately two-thirds of patients with treatment-refractory headache disorders reported improvement with off-label suzetrigine, supporting further prospective evaluation of the selective NaV1.8 inhibitor.

A new phase 2 trial, presented at AAIC 2026, aims to evaluate the effects of urolithin A on mitophagy/autophagy activity, oxidative stress, multi-omic profiling, and cognitive function in APOE4 carriers.

The approval allows patients to begin lecanemab treatment at home via weekly subcutaneous injection, eliminating the 18-month IV requirement that previously preceded any at-home dosing.